Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort  by Postorino, M.C. et al.
ORIGINAL ARTICLE VIROLOGYUse of efavirenz or atazanavir/ritonavir is associated with better clinical
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ItalyAbstractRandomized trials and observational cohorts reported higher rates of virological suppression after highly active antiretroviral therapy
(HAART) including efavirenz (EFV), compared with boosted protease inhibitors (PIs). Correlations with immunological and clinical
outcomes are unclear. Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Outstanding
outcome (composite outcome for success (COS)) was introduced. We evaluated predictors of COS (no AIDS plus CD4+ count >500/
mm3 plus HIV-RNA <500 copies/mL) and of eight single outcomes either at month 6 or at year 3. Multivariable logistic regression was
conducted. There were 6259 patients selected. Patients on EFV (43%) were younger, had greater CD4+ count, presented with AIDS less
frequently, and more were Italians. At year 3, 90% of patients had HIV RNA <500 copies/mL, but only 41.4% were prescribed EFV, vs.
34.1% prescribed boosted PIs achieved COS (p <0.0001). At multivariable analysis, patients on lopinavir/ritonavir had an odds ratio of
0.70 for COS at year 3 (p <0.0001). Foreign origin and positive hepatitis C virus-Ab were independently associated with worse outcome
(OR 0.54, p <0.0001 and OR 0.70, p 0.01, respectively). Patients on boosted PIs developed AIDS more frequently either at month 6
(13.8% vs. 7.6%, p <0.0001) or at year 3 (17.1% vs. 13.8%, p <0.0001). At year 3, deaths of patients starting EFV were 3%, vs. 5% on
boosted PIs (p 0.008). In this study, naïve patients on EFV performed better than those on boosted PIs after adjustment for imbalances at
baseline. Even when virological control is achieved, COS is relatively rare. Hepatitis C virus-positive patients and those of foreign origin
are at risk of not obtaining COS.
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p://dx.doi.org/10.1016/j.cmi.2014.10.022IntroductionThe 2014 guidelines for management of human immunodeﬁ-
ciency virus (HIV) infection recommended highly active anti-
retroviral therapy (HAART), including two nucleoside/
nucleotide reverse transcriptase inhibitors (N(t)RTIs) as
backbone, associated with a non-nucleoside reverseious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Postorino et al. Short and mid-term predictors of clinical outcomes during HAART 386.e2transcriptase inhibitor (NNRTI), a ritonavir-boosted protease
inhibitor (PI/r), or an integrase strand transfer inhibitor as
anchor drugs [1].
Although not invariably [2,3], randomized clinical trials re-
ported higher rates of virological suppression with NNRTIs as
compared to boosted PIs [4–7]. Some observational studies
conﬁrmed higher rates of virological success after efavirenz
(EFV) initiation when compared with boosted PIs [8–10], whilst
other cohort studies did not reveal marked differences in terms
of virological end points [11–13]. However, boosted PIs may
perform better than EFV when immunological success rates
were considered [10]. Also, reported rates of AIDS events and
deaths were similar for patients treated with either EFV or
boosted PIs in observational cohort studies [11–13].
Even more controversial results were obtained when
comparing different boosted PIs. For instance, in a recent trial, a
similar incidence of virological failures has been reported at
week 96, although treatment discontinuations of therapy
occurred more frequently in patients on atazanavir boosted by
ritonavir (ATV/r) (14%) than in those on darunavir/r (DRV/r)
(5%) [14]. Nonetheless, randomized clinical trials are often
unable or unpowered to relate results of viro-immunological
responses with clinical outcomes.
This study aimed at comparing rates of death, AIDS events,
non-AIDS events, changes of anchor drugs, virological sup-
pression, and immunological response among patients treated
with EFV or boosted PIs in ﬁrst line and to analyse predictors of
the clinical response. In addition to single/separate end points
[8–12], this study evaluated composite outcomes, which
included at the same time CD4+ T cell count, viral load, and
AIDS events, both at mid-term (3 years) and at short-term (6
months) follow-up.MethodsThe MASTER is a multi-centre cohort study that involves 10
major Italian centres for HIV care. Data of HIV-infected patients
from each of these centres are collected, revised, and shared
with periodic updates using a common electronic database
(Health & Notes 3.5®, Healthware S.p.A., Naples, Italy),
creating a large longitudinal observational cohort of 24 814
patients as of January 2013.
In this study, HIV-infected adults who started a ﬁrst-line
HAART from January 1 2000 to December 31, 2010 were
selected. HAART had to include two N(t)RTIs as backbone, and
a boosted PI or EFV as anchor drugs (no other NNRTIs were
considered). Prescribed PIs were DRV, lopinavir (LPV) or ATV,
all boosted with ritonavir (r). Patients were divided into two
groups by class of anchor drug (EFV vs. boosted PI).Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InPatient baseline characteristics were collected according to
time of ﬁrst-line therapy (searching for the most recent mea-
sure up to 90 days prior to treatment initiation). The following
characteristics were considered: age, calendar year, gender,
mode of HIV transmission, nationality, hepatitis co-infection
(hepatitis C virus antibody (HCV-Ab) and/or hepatitis B sur-
face antigen (HBsAg) positivity), HIV RNA load (expressed as
log10 copies/mL), CD4+ T cell count, CD4+ T cell percentage,
HAART backbone, type of anchor drug (EFV or boosted PI),
any prior AIDS-deﬁning event and time from HIV diagnosis to
baseline. Date of the latest follow-up, death, and stopping date
of anchor drugs were also reported.
The ﬁrst evaluation of outcomes was ﬁxed at month 6 from
baseline. At this time point, HIV RNA, CD4+ T cell count,
death, and any AIDS or non-AIDS events were collected closer
to month 6 and after at least 90 days from baseline.
Second follow-up was ﬁxed at year 3. The same set of var-
iables was considered, all closer to year 3 and collected after at
least 2 years from baseline.
Eight single binary outcomes were deﬁned and assessed at
each time point: HIV RNA below 500 copies/mL, CD4+ T cells
below 350/mm3, CD4+ T cells below 500/mm3, AIDS event,
non-AIDS event, death for any cause, change of the anchor
drug, and status of the follow-up (continuing or interrupted).
The 500 copies/mL cut-off for HIV RNA was chosen to avoid
possible bias related to disparities in the use of ultrasensitive
tests that occurred after the beginning of this study. In addition,
two composite outcomes deﬁning clinical success and one
composite outcome deﬁning clinical failure were deﬁned.
Although the use of composite outcomes may be misleading
because in many cases it is difﬁcult to discriminate between
results applied to the individual components of the outcome
(for which we also analysed these individual components),
clinical trials are employing these outcomes in the HIV ﬁeld
[15]. The ﬁrst composite outcome for success (COS) included
no AIDS events plus CD4+ T cell count above 500/mm3 plus
HIV RNA below 500 copies/mL. The second one included the
same variables plus continuing the initial drug used as anchor.
Composite outcome for failure included any AIDS event or
death plus CD4+ T cell count below 500/mm3 plus HIV RNA
500 copies/mL. All outcomes were evaluated either at short
term or at mid term. The analysis was conducted for the above
outcomes, ignoring changes of the backbone drugs. Only pa-
tients observed at each time point contributed data in the
analysis.
Appropriate statistical methods were used: descriptive
stratiﬁed statistics, χ2 on cross tabulations, Wilcoxon rank-sum
tests, Student’s t tests, multivariable logistic regression
(adjusting for all baseline variables), and calculation of area
under the receiver operating characteristics curve to evaluatefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 386.e1–386.e9
386.e3 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIperformances of models [16] on selected outcomes. A sup-
plementary, explorative analysis was performed for immuno-
logical, virological, and clinical end points at mid term, including
univariable and multivariable logistic regression with all the
above and number/reasons of the drug switches (any) as vari-
ables. Since the analysis was aimed at investigating the outcomes
in those with observed data at ﬁxed time points, in line with our
previous study [10], a survival analysis was not performed. This
has the drawback of ignoring outcomes occurring before the
pre-deﬁned time points. To address this issue, we performed
analyses that included outcomes occurring before the stated
time points and also that included patients lost to that speciﬁc
end point (e.g. missing a required measure for calculating the
outcome) by assigning them to one or the other class (results
provided in the Supplementary Material).ResultsPatient characteristics
Overall, 6259 patients were included in this study. Patients
starting boosted PIs (57%) outnumbered those initiating EFV
(43%). Among patients treated with boosted PIs, 63.3% were
prescribed LPV/r, 27.1% ATV/r, and 9.4% DRV/r. Italian patients
were 74%, males 73%, intravenous drugs users 13.3%, homo-
sexuals 20.6%, and heterosexuals 42.9%. Eighteen per cent ofTABLE 1. Characteristics of population at baseline
EFV (n [ 2695) Boosted PI
Qualitative variables
Gender
Female 601 (22.3%) 1006 (28.3
Male 2094 (77.7%) 2558 (71.7
HBsAg
Negativity/unknown 2287 (84.8%) 2834 (79.5
Positivity 408 (15.2%) 730 (20.5
HCV-Ab
Negativity/unknown 2216 (82.2%) 2879 (80.8
Positivity 479 (17.8%) 685 (19.2
Nationality
Italian 2209 (81.9%) 2842 (79.7
Non-Italian/unknown 486 (18.1%) 722 (20.3
Risk factor
Heterosexual 1209 (44.9%) 1474 (41.3
Homosexual 657 (24.4%) 637 (17.9
IVDU 343 (12.7%) 490 (13.7
Other/unknown 486 (18%) 963 (27.1
AIDS events
No 2263 (83.9%) 2866 (80.4
Yes 432 (16.1%) 698 (19.6
Quantitative variables, mean (SD)
Age 39.64 (10.05) 40.41 (10.2
CD4+ T cells/mm3 a 265.96 (179.00) 232.78 (92.4
CD4+ T cells %b 15.98 (8.50) 15.46 (9.86
Log10 HIV RNA copies/mL
c 4.39 (1.04) 4.42 (1.08
Calendar year 2006.26 (3.59) 2007.53 (2.97
p Value is expressed as result of t-test (age and log10 HIV-RNA load), Wilcoxon test (other
EFV, efavirenz; HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; HIV
aPatients observed: 5285.
bPatients observed: 4908.
cPatients observed: 5233.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpatients had at least one AIDS event reported prior to or at
baseline. HBsAg carriers accounted for 15% of cases on EFV
and for 20.5% on boosted PIs. Positivity for HCV-Ab accounted
for 18% of patients in the EFV group and for 19.2% in the
boosted PI group. As compared to patients on boosted PIs,
those on EFV were younger (mean: 39.6 vs. 40.1 years; p
0.0027), had higher CD4+ T cell count (mean: 266 vs. 233 cells/
mm3, p <0.0001), fewer had AIDS events before HAART
initiation (16% vs. 19.5%, p 0.0003), and were more frequently
Italians (82% vs. 80, p 0.0279) (Table 1).
Outcomes
Figure 1 summarizes single and composite outcomes at month
6 (panel a) and at year 3 (panel b). Charts are stratiﬁed by type
of anchor drug prescribed.
Ninety per cent of patients had an HIV-RNA load <500
copies/mL at month 6 (91% in the EFV group, 89.5% in the
boosted PI group (p <0.0001)). HIV RNA <500 copies/mL was
found in 90.3% of patients at year 3 (91.3% in the EFV group,
89.4% in the boosted PI group (p 0.0587)). When looking at the
immunological outcome, 44.1% of patients had CD4+ T cells
above 500/mm3 at year 3 (47.8% in the EFV group, 40.6% on
boosted PI (p <0.0001)).
AIDS-related events occurred more frequently in the
boosted PI group than in the EFV group, both at month 6
(13.8% vs. 7.6%, p <0.0001) and at year 3 (17.1% vs. 13.8%, p(n [ 3564) Total (n [ 6259) p
%) 1607 (25.7%) <0.0001
%) 4652 (74.3%)
%) 5121 (81.8%) <0.0001
%) 1138 (18.2%)
%) 5095 (81.4) 0.149
%) 1164 (18.6%)
%) 5051 (80.7%) 0.0279
%) 1208 (19.3%)
%) 2683 (42.9%) <0.0001
%) 1294 (20.6%)
%) 833 (13.3%)
%) 1449 (23.1%)
%) 5129 (81.9%) 0.0003
%) 1130 (18.0%)
7) 40.08 (10.18) 0.0027
4) 247.38 (187.35) <0.0001
) 15.69 (9.28) 0.04778
) 4.41 (1.06) 0.2618
) 2006.99 (3.3) <0.0001
numeric variables) or Fisher test (discrete variables).
, human immunodeﬁciency virus; IVDU, intravenous drugs users; PI, protease inhibitor.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 386.e1–386.e9
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FIG. 1. Selected unadjusted outcomes (%) at (a) month 6 and at (B) year 3. ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; EFV, efavirenz; EFV/
FTC/TDF, efavirenz/emtricitabine/tenofovir (co-formulated); LPV/r, lopinavir/ritonavir.
CMI Postorino et al. Short and mid-term predictors of clinical outcomes during HAART 386.e4<0.0001). At year 3, deaths in the EFV group were 3%, vs. 5% in
the boosted PI group (p 0.008).
Change of anchor drugs occurred in 27.8% of patients
starting EFV and in 19.3% of patients starting boosted PIs at
month 6, increasing to 67.5% and 66%, respectively, at year 3 (p
<0.001). COS was achieved by 22.6% of patients at month 6
(24.8% EFV, 20.8% boosted PIs (p 0.0011)), and by 38.7% of
patients observed at year 3 (41.4% EFV and 34.1% boosted PIs
(p <0.0001)).
Predictors of composite outcome of success
Table 2 reports univariable and multivariable logistic regression
analyses for COS either at month 6 or at year 3.
In details, patients who started HAART more recently had
higher odds to reach COS at year 3 (OR 1.09 per increasing
calendar year, 95% CI 1.04–1.14, p <0.0001), whilst older pa-
tients had lower odds (OR 0.85, 95% CI 0.78–0.92, p <0.0001).
Foreign origin was associated with a decreased probability of
obtaining COS either at short (OR 0.64, 95% CI 0.50–0.82, p
0.0004) or at mid term (OR 0.67, 95% CI 0.54–0.84, p 0.0004).
Positivity for HCV-Ab was also associated with a lower prob-
ability of obtaining COS at year 3 (OR 0.66, 95% CI 0.51–0.84,
p 0.0008), but this association was not signiﬁcant at month 6.
AIDS events at baseline were associated with a lower risk ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inreaching COS either at month 6 (OR 0.50, 95% CI 0.36–0.68, p
<0.0001) or at year 3 (OR 0.63, 95% CI 0.51–0.78, p <0.0001).
As expected, patients with a CD4+T cell count at baseline >200
cells/mm3 showed a higher probability of reaching COS, either
at short or at mid term.
Patients who started LPV/r showed an OR of COS of 0.70
(95% CI 0.58–0.85, p 0.0002) when compared to patients on
EFV at year 3. Instead, differences among anchor drugs could
not be found signiﬁcant at the 0.05 level at month 6.
Predictors of single outcomes
Probability of virological success was decreased in foreign pa-
tients compared to Italian patients, either at month 6 (OR 0.54,
95% CI 0.42–0.70, p <0.0001) or at year 3 (OR 0.61, 95% CI
0.45–0.82, p 0.0013). Likewise, in terms of immunological
response, foreign origin was associated with a decreased
probability of reaching CD4+ T cell count above 500/mm3
either at short term (OR 1.53, 95% CI 1.20–1.94, p 0.0006) or
at mid term (OR 1.67, 95% CI 1.34–2.07, p <0.0001). Patients
on EFV had a signiﬁcant increased risk of changing anchor drugs
at month 6 than those on boosted PIs (for LPV/r: OR 0.59, 95%
CI 0.51–0.69, p <0.0001; for DRV/r: OR 0.24, 95% CI
0.17–0.35, p <0.0001, and for ATV/r: OR 0.31, 95% CI
0.25–0.39, p <0.0001)).fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 386.e1–386.e9
TABLE 2. Composite outcome for success (COS) at month 6 and at year 3 (no AIDS events plus CD4+ T cell counts above 500/
mm3plus HIV RNA below 500 copies/mL)
Variables
Univariable analysis at
month six
Multivariable analysis
at month six
Univariable analysis
at year three
Multivariable analysis
at year three
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Calendar year 1.14 (1.11–1.17) <0.0001 1.12 (1.07–1.17) <0.0001 1.14 (1.11–1.17) <0.0001 1.09 (1.04–1.14) 0.0004
EFV/TDF/FTC vs. EFV 1.97 (1.46–2.64) <0.0001 — — 1.66 (1.16–2.38) 0.0058 — —
LPV/r vs. EFV 0.61 (0.52–0.73) <0.0001 — — 0.58 (0.50–0.67) <0.0001 0.72 (0.60–0.87) 0.0006
DRV/r vs. EFV 1.00 (0.74–1.36) 0.9867 — — 0.62 (0.37–1.04) 0.0700 0.53 (0.29–0.97) 0.0392
ATV/r vs. EFV 1.56 (1.29–1.89) <0.0001 — — 1.47 (1.18–1.82) 0.0005 — —
3TC-AZT vs. 3TC-ABC 0.86 (0.65–1.14) 0.2855 — — 0.63 (0.49–0.82) 0.0006 — —
3TC-D4T vs. 3TC-ABC 0.31 (0.17–0.55) <0.0001 — — 0.45 (0.30–0.69) 0.0002 — —
3TC-DDI vs. 3TC-ABC 0.91 (0.62–1.34) 0.6213 1.67 (1.02–2.74) 0.0411 0.72 (0.51–1.03) 0.0715 — —
3TC-TDF vs. 3TC-ABC 0.69 (0.47–1.01) 0.0562 — — 0.68 (0.49–0.94) −0.0205 — —
ABC-DDI vs. 3TC-ABC 0.84 (0.42–1.68) 0.6161 — — 1.01 (0.56–1.83) 0.9763 — —
AZT-TDF vs. 3TC-ABC 0.68 (0.33–1.40) 0.2973 — — 0.63 (0.34–1.17) 0.1447 0.50 (0.25–1.00) 0.0501
D4T-DDI vs. 3TC-ABC 0.12 (0.02–0.86) 0.0347 — — 0.29 (0.11–0.77) 0.0133 — —
DDI-TDF vs. 3TC-ABC 0.54 (0.20–1.43) 0.2134 — — 0.55 (0.26–1.18) 0.1268 — —
FTC-TDF vs. 3TC-ABC 1.11 (0.86–1.42) 0.4246 — — 1.17 (0.92–1.50) 0.2005 — —
Other backbone vs. 3TC-ABC 1.79 (1.26–2.54) 0.0012 — — 1.29 (0.88–1.90) 0.1963 — —
Age 0.76 (0.71–0.82) <0.0001 0.83 (0.76–0.91) <0.0001 0.82 (0.76–0.88) <0.0001 0.84 (0.78–0.92) <0.0001
Gender male vs. female 0.89 (0.76–1.04) 0.1370 — — 0.93 (0.80–1.08) 0.3293 — —
Non-Italian/unknown nationality 0.78 (0.65–0.94) 0.0097 0.64 (0.50–0.82) 0.0004 0.76 (0.63–0.91) 0.0033 0.67 (0.53–0.83) 0.0003
Homosexual vs. heterosexual 1.45 (1.22–1.72) <0.0001 — — 1.54 (1.31–1.82) <0.0001 — —
Injection drug user vs. heterosexual 0.81 (0.64–1.03) 0.0808 — — 0.87 (0.70–1.07) 0.1821 — —
Other/unknown risk factor vs.
heterosexual
1.25 (1.04–1.50) 0.0177 — — 1.09 (0.90–1.32) 0.3635 — —
CD4+T cells 200 - 350
vs. <200 cells/mm3
13.17 (9.51–18.25) <0.0001 10.79 (7.66–15.22) <0.0001 6.08 (5.08–7.27) <0.0001 5.02 (4.09–6.17) <0.0001
CD4+T cells 350 -500
vs. <200 cells/mm3
47.26 (33.78–66.13) <0.0001 41.81 (29.12–60.02) <0.0001 9.10 7.23–11.45 <0.0001 7.85 (6.04–10.19) <0.0001
CD4+ T cells >500
vs. <200 cells/mm3
135.70 (91.29–201.71) <0.0001 148.61 (96.62–228.57) <0.0001 8.61 6.28–11.81 <0.0001 8.69 (6.11–12.36) <0.0001
CD4+ T cells unknown
vs. <200 cells/mm3
9.99 (6.57–15.20) <0.0001 9.32 (5.07–17.14) <0.0001 2.41 1.86–3.12 <0.0001 2.69 (1.68–4.30) <0.0001
HIV-RNA load 500–5000
vs. <500 copies/mL
0.94 (0.73–1.22) 0.6497 — 1.04 0.79–1.37 0.7714 — —
HIV-RNA load 5000–50 000
vs. <500 copies/mL
0.89 (0.72–1.12) 0.3251 1.68 (1.26–2.24) 0.0004 1.12 0.88–1.41 0.3524 — —
HIV-RNA load >50 000
vs. <500 copies/mL
0.65 (0.53–0.80) <0.0001 2.57 (1.94–3.40) <0.0001 0.90 (0.73–1.11) 0.3272 1.88 (1.45–2.44) <0.0001
HIV-RNA load unknown
vs. <500 copies/mL
0.63 (0.46–0.88) 0.0057 1.99 (1.12–3.54) 0.0185 0.70 (0.53–0.92) 0.0104 — —
HBsAg positive vs. negative 0.84 (0.70–1.00) 0.0567 — — 0.96 (0.82–1.14) 0.6670 1.23 (1.01–1.50) 0.0371
HCV-Ab positive vs. negative 0.83 (0.69–1.00) 0.0498 — — 0.69 (0.58–0.82) <0.0001 0.68 (0.53–0.87) 0.0019
Time from infection to
baseline > 2 years vs. <6 months
2.24 (1.90–2.64) <0.0001 1.28 (1.04–1.58) 0.0190 2.20 (1.87–2.58) <0.0001 1.37 (1.13–1.66) 0.0013
Time from infection to baseline 6
months–2 years vs. <6 months
2.70 (2.23–3.26) <0.0001 1.33 (1.05–1.68) 0.0170 2.72 (2.24–3.30) <0.0001 1.45 (1.15–1.81) 0.0014
Time from infection–baseline
unknown vs. <6 months
2.48 (1.70–3.61) <0.0001 — — 1.42 (0.55–3.69) 0.4670 — —
AIDS events 0.23 (0.18–0.30) <0.0001 0.50 (0.36–0.68) <0.0001 0.36 (0.30–0.44) <0.0001 0.65 (0.52–0.80) <0.0001
Number of switches in the follow-up 0.92 (0.90–0.95) <0.0001 0.96 (0.92–1.00) 0.0680 0.88 (0.86–0.91) <0.0001 0.88 (0.85–0.91) <0.0001
ABC, abacavir; ATV/r, atazanavir/ritonavir, AZT, zidovudine; DDI, didanosine; DRV/r, darunavir/ritonavir; D4T, stavudine; EFV, efavirenz; EFV/FTC/TDF, efavirenz/emtricitabine/
tenofovir (co-formulated); HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; HIV, human immunodeﬁciency virus; LPV/r, lopinavir/ritonavir; TDF, tenofovir;
3TC, lamivudine.
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inclusion criteria
Fifty-eight per cent of patients (n = 3625) switched to other
regimens at year 3 (46% after initial EFV and 54% after boosted
PIs; 16% of patients for toxicity and 6% for virological failure).
Reasons and number of switches were included in the multi-
variable analysis for outcomes at mid term (HIV RNA <500
copies/mL, CD4+T cells <500/mm3, AIDS events, non-AIDS
events, death, and COS at year 3).
Odds ratios obtained for death at year 3 conﬁrmed results of
the multivariable logistic regression analysis when reasons and
number of switches were not included. Patients with a CD4+ T
cell count between 200 and 350/mm3 vs. patients with <200
cells/mm3 at baseline had a lower risk of death at year 3 (ORClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect0.40, 95% CI 0.26–0.63, p <0.0001). Older patients (OR 1.57,
95% CI 1.35–1.82, p <0.0001), patients with AIDS events at
baseline (OR 1.73, 95% CI 1.25–2.38, p <0.0001), patients on
DRV/r (OR 5.48, 95% CI 2.42–12.44, p <0.0001) and started
on ATV/r (OR 2.96, 95% CI 1.78–4.93, p <0.0001) showed a
greater risk of death at year 3. Patients who switched vs. pa-
tients who continued their regimen had an increased risk of
death at year 3, especially those who switched for other/un-
known reasons (OR 32.69, 95% CI 13.88–76.99, p <0.0001).
The same variables maintained their statistical signiﬁcance for
associations with COS at multivariable analysis. Results by an-
chor drug prescribed showed that patients started on LPV/r had
an OR of 0.71 (95% CI 0.59–0.85, p 0.0003), and on DRV/r had
an OR of 0.54 (95% CI 0.29–0.59, p 0.045) for COS at year 3ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 386.e1–386.e9
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outstanding outcome decreased in patients who switched for
virological failure (OR 0.36, 95% CI 0.24–0.55, p <0.0001).
Number of switches was associated also with lower probability
of reaching COS at year 3 (OR 0.89, 95% CI 0.85–0.93, p
<0.0001) (Fig. 2).
Prediction performance of ﬁtted models
Analysis of receiver operating characteristics was performed to
estimate the best-ﬁtting models to predict outcomes. Calcula-
tion of area under the receiver operating characteristics curve
showed good performances of models applied in this study. In
particular, COS at month 6 had an area under the curve of 0.87
(Fig. 3).DiscussionThis study evaluated clinical, virological, and immunological
responses of HIV treatment in naïve patients starting a ﬁrst-line
HAART including either EFV or boosted PIs, at month 6 and at
year 3. With this objective in mind, we deﬁned a composite
outcome of success (COS) and also weighted the individual
components of this outcome.
In spite of reaching a good virological outcome (about 90% of
the observed patients reached virological success at year 3),
COS was reached in only a fraction (about 40%) of patients
observed. Since any of the components of COS are signiﬁcant
for patients’ health [17,18], it is important to study predictors
for this kind of response.
One of the main variables studied as predictors was the
anchor drug prescribed in the ﬁrst-line regimen. Patients on
EFV had a greater probability of reaching COS than patients on
boosted PIs at year 3. Indeed, patients on LPV/r (the most
frequently prescribed PI) had a greater risk of missing COS atFIG. 2. Percentage of patients reaching the composite outcome for success
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inyear 3 than those on EFV. It is, however, important to consider
that patients on PI/r were more advanced than those prescribed
EFV. So, although these results were conﬁrmed by the multi-
variable logistic regression analysis to adjust for imbalances at
baseline, this comparison may suffer from a channelling bias.
Moreover, it should be considered that period of follow-up is
relatively short: longer periods of virological suppression may
be needed to observe a comparable immune-reconstitution
among the treatment groups. Nonetheless, if one assumes
that initial virological suppression is a reliable surrogate marker
for clinical success even at longer term, the results presented
herein extend our previous observations [10] and seem to
conﬁrm trial results in clinical practice [2].
Perhaps the more outstanding ﬁnding was that patients pre-
scribed ATV/r did not differ signiﬁcantly from patients on EFV
except for the mortality outcome (which may be more subjected
to clinical conditions at baseline, however). The ACTG A5202
trial [19] did not reveal signiﬁcant difference in terms of viro-
logical outcome for EFV compared to ATV/r. So, our results may
be interpreted as a further clinical correlate for this ﬁnding [19],
in line with reports of other observational cohorts [20], but in
contrast to other evidence from clinical practice [21]. Also, the
ACTG trial 5257, recently updated with results at week 96,
showed that patients on ATV/r suffered from quite a signiﬁcant
risk of therapy discontinuations (e.g. 14% vs. 5% DRV/r) [14]. In
our observational study, no signiﬁcant differences in the rate of
switching were observed between patients treated with ATV/r
or with DRV/r. Also, the analysis of COS did not demonstrate
any signiﬁcant difference between ATV/r and EFV. So, conditions
in real life may reduce the applicability of clinical trials to a sig-
niﬁcant extent. In particular, jaundice or its perception had a
great impact on the risk of therapy discontinuation in the ACTG
5257 trial [14], while in clinical practice, high grade of hyper-
bilirubinemia and discontinuations for jaundice are not so
frequent [22]. Altogether, our results underline the complexityat year 3 by switch occurred along the follow-up.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 386.e1–386.e9
FIG. 3. Receiver operating characteristic (ROC) curves in cross-validation showing performances of best models (only those achieving an area under
the ROC of 80% or more). AUC: area under the ROC curve.
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interpret differences from clinical trials.
Interestingly, many patients switched off the initial anchor
drug (>50% overall after 3 years), and the ﬁnal outcome may
not be referred to the ﬁrst treatment choice. For this reason,
we investigated the possible impact of number and reasons for
therapy switches. Our study showed a lower probability of
obtaining COS in patients who switched for virological failure
vs. patients who switched for other reasons and in those who
switched several times, but the switch did not appear to modify
the impact of the remaining variables to a signiﬁcant extent.
Foreign origin was signiﬁcantly associated with worse out-
comes (including COS), independently from possible con-
founders at baseline. A cohort study recently reported a so-
called “healthy migrant effect,” describing a lower mortality at
year 4 in foreign patients vs. natives [23], although the same
cohort reported higher incidence of AIDS (in particular,
tuberculosis) in migrants during the ﬁrst year of antiretroviral
therapy [24]. In the Dutch cohort, foreign patients were lessClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectlikely to achieve virological suppression and experienced more
frequent diseases and death [25], even though other European
cohorts did not report marked differences in AIDS, death, and
access to therapy [26,27]. Although a multivariable analysis was
performed, we cannot exclude that our results can be due to a
greater proportion of foreign patients treated with less toler-
able and more complicated regimens including boosted PI
(especially the soft-gel LPV/r formulation) in the earlier 2000. In
any case, our study suggests that attention should be paid to
migrants who actually represent a signiﬁcant proportion of
those under care throughout Italy [28].
In this study, patients with positive HCV-Ab had a lower
probability of reaching COS at year 3. By contrast, signiﬁcant
results were not observed in HBsAg carriers included in our
study. The issue of differences in viro-immunological outcome
after HAART is still unresolved [29,30]. However, when clinical
outcomes are considered, HIV/HCV-co-infected patients
showed a consistent increased risk of mortality for liver disease
than HIV-mono-infected individuals [31].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 386.e1–386.e9
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the evaluation of observational data. In our case this may be
relevant given the differences in the population strata (i.e.
possible bias by indication). In any observational cohort study, it
is impossible to exclude selection and/or channelling biases.
Also, we studied only patients with available measures, so a
“selection of the ﬁt” effect could be present. Survival analyses
were not performed because we were primarily interested in
describing the outcome of observed patients at pre-deﬁned
time points, in analogy to previous analysis conducted by the
same group [10]. However, consideration of outcomes varia-
tions, including also patients with partially available measures,
conﬁrmed the results of the main analysis (see Supplementary
Materials). Lastly, speciﬁc adverse events or non-AIDS events
were not evaluated. Non-AIDS events were only collectively
evaluated, providing weak evidence of correlation with out-
comes. Consideration of individual non-AIDS events would
probably require a greater cohort of patients.
In conclusion, the present study showed that a good viro-
logical response was not coupled with COS compared to pa-
tients who received EFV, but not to those who received
modern PI/r such as ATV/r. Patients at an advanced stage of the
disease, of foreign origin, with positive HCV-Ab, and those who
received a boosted PI (in particular LPV/r) in the ﬁrst-line
regimen, are at a greater risk of not achieving COS. So, opti-
mization of HAART remains important, especially in the fragile
populations of migrant patients who present late, and with HIV/
HCV co-infection.
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